4,132 results match your criteria Chordoma


Clival Chondroid Chordoma: A Case Report and Review of the Literature.

Cureus 2018 Sep 28;10(9):e3381. Epub 2018 Sep 28.

Department of Internal Medicine, Hospital Teodoro Maldonado Carbo / Universidad Catolica De Santiago De Guayaquil, Guayaquil, ECU.

Chordomas are rare, slow-growing, and locally aggressive malignant neoplasms derived from primitive notochord remnants. The chondroid variety represents 14% of all chordomas mainly developing in the spheno-occipital region and presenting between the third and fifth decades of life. When developing intracranially, symptoms can range from headaches and neck pain to cranial nerve neuropathies and facial numbness. Read More

View Article
September 2018

Adjuvant gamma knife surgery and image-guided, intensity-modulated radiation therapy for the treatment of sacral chordomas.

Rep Pract Oncol Radiother 2019 Jan-Feb;24(1):74-79. Epub 2018 Nov 22.

Department of Radiotherapy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, China.

Aim: The aim of this study was to confirm whether patients with sacral chordoma benefit from adjuvant radiotherapy and to determine the optimal photon radiotherapy module for comprehensive treatment.

Background: Chordoma is a rare slow-growing neoplasm arisen from cellular remnants of the notochord. About 50% occur in the sacrococcygeal region. Read More

View Article
November 2018

[A giant sacral chordoma resection and reconstruction with a gluteal perforator flap, a case report and literature review].

Ann Chir Plast Esthet 2018 Nov 30. Epub 2018 Nov 30.

Service de chirurgie orthopédique et traumatologie, chirurgie du rachis, hôpital Bicêtre, 78, rue du Général-Leclerc, 94270 Le Kremlin-Bicêtre, France.

Background: Sacral chordomas are rare primary bone tumors and represent more than half of all primary malignant sacral tumors. Surgical resection is the only treatment with close to 50% of remission at 10 years, with or without radiotherapy. This tissue removal can be very extensive and morbid, particularly for evolved tumors. Read More

View Article
November 2018

Current treatment strategy for newly diagnosed chordoma of the mobile spine and sacrum: results of an international survey.

Authors:

J Neurosurg Spine 2018 Oct 1:1-7. Epub 2018 Oct 1.

OBJECTIVEThe purpose of this study was to investigate the spectrum of current treatment protocols for managing newly diagnosed chordoma of the mobile spine and sacrum.METHODSA survey on the treatment of spinal chordoma was distributed electronically to members of the AOSpine Knowledge Forum Tumor, including neurosurgeons, orthopedic surgeons, and radiation oncologists from North America, South America, Europe, Asia, and Australia. Survey participants were pre-identified clinicians from centers with expertise in the treatment of spinal tumors. Read More

View Article
October 2018

Chordoma of the corpus callosum: case report.

Authors:

J Neurosurg 2018 Nov 1:1-7. Epub 2018 Nov 1.

Chordomas are neoplasms that typically arise from midline skeletal structures and rarely originate within the intradural compartment of the CNS. A chordoma arising from the corpus callosum has not been previously described. The authors report the surgical management of a chordoma originating within the splenium of the corpus callosum. Read More

View Article
November 2018
2 Reads

Immunotherapy utilizing the combination of natural killer- and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition.

J Immunother Cancer 2018 Nov 29;6(1):133. Epub 2018 Nov 29.

Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Room 8B09, Bethesda, MD, 20892, USA.

Background: Poly (ADP-ribose) polymerase inhibitors (PARPi) prevent single-stranded DNA repair. Olaparib is a PARPi approved for the treatment of BRCA mutant ovarian and breast carcinoma. Emerging clinical data suggest a benefit of combining olaparib with immunotherapy in prostate cancer patients both with and without somatic BRCA mutations. Read More

View Article
November 2018
6 Reads

Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.

Lancet Oncol 2018 Nov 23. Epub 2018 Nov 23.

Medical Oncology Department, Centre Léon Bérard, Lyon, France.

Background: Regorafenib has proven activity in patients with pretreated gastrointestinal stromal tumours and colorectal and hepatocellular carcinoma. We designed REGOBONE to assess the efficacy and safety of regorafenib for patients with progressive metastatic osteosarcoma and other bone sarcomas. This trial comprised four parallel independent cohorts: osteosarcoma, Ewing sarcoma, chondrosarcoma, and chordoma. Read More

View Article
November 2018
2 Reads

Treatment outcomes of proton or carbon ion therapy for skull base chordoma: a retrospective study.

Radiat Oncol 2018 Nov 26;13(1):232. Epub 2018 Nov 26.

Department of Radiology, Hyogo Ion Beam Medical Center, Tatsuno, Hyogo, Japan.

Background: The usefulness of particle therapy for skull base chordoma has not been established. The aim of this retrospective study was to analyse the treatment outcomes of proton therapy (PT) and carbon ion therapy (CIT) in patients with skull base chordoma at a single institution.

Methods: All patients who underwent PT or CIT with curative intent between 2003 and 2014 at Hyogo Ion Beam Medical Center were included in this study. Read More

View Article
November 2018
2 Reads

Letter to the Editor Regarding "Comparison of the Effectiveness of Radiotherapy with Photons and Particles for Chordoma After Surgery: A Meta-Analysis".

Authors:
Ensiyeh Jenabi

World Neurosurg 2018 12;120:603

Pediatric Developmental Disorders Research Center, Hamadan University of Medical Sciences, Hamadan, Iran. Electronic address:

View Article
December 2018

Gamma Knife Management of Skull Base Chordomas: Is it a Choice?

Asian J Neurosurg 2018 Oct-Dec;13(4):1037-1041

Department of Neurosurgery, Mansoura University Hospital, Mansoura, International Medical Center, Cairo, Egypt.

Background: Skull base chordomas are locally invasive tumors which able to extend in different directions with skull base invasion. Although they are histologically benign, they have invasive nature makes total resection virtually impossible to achieve in most cases and this lead to residual tumors after surgery. To decrease postoperative surgical resection morbidity of these tumors, gamma knife radiosurgery (GKRS) was performed as alternative management for these residual chordomas to evaluate its safety and efficacy. Read More

View Article
November 2018
2 Reads

Novel approach using transoral robotic surgery for resection of cervical spine chordoma.

Laryngoscope 2018 Nov 19. Epub 2018 Nov 19.

Department of Otorhinolaryngology-Head and Neck Surgery.

Chordomas are rare, infiltrative neoplasms of notochordal origin that present along the spinal canal; en bloc surgical resection is paramount to successful treatment. Limited visualization and complex anatomy are major challenges to resection of upper cervical spine chordomas and often require invasive surgery. A 27-year-old male presented with an incidentally discovered chordoma of the midline second cervical vertebra of the spine. Read More

View Article
November 2018
7 Reads

Pediatric Endoscopic Endonasal Approaches for Skull Base Lesions in the Very Young: Is It Safe and Effective?

J Neurol Surg B Skull Base 2018 Dec 30;79(6):574-579. Epub 2018 Apr 30.

Department of Neurosurgery, University of California San Diego, San Diego, California, United States.

 The fully endoscopic expanded endonasal approach (EEA) has been shown to be safe and efficacious in pediatric patients. However, in the very young patient (ages six and under), the anatomical challenge of working through a small nasal corridor is problematic. The ability to repair the skull base and use a nasoseptal flap (NSF) has also been called into question. Read More

View Article
December 2018

Sacral chordoma: a clinical review of 101 cases with 30-year experience in a single institution.

Spine J 2018 Nov 14. Epub 2018 Nov 14.

Department of Orthopaedic Surgery, Orthopaedic Oncology Service, Massachusetts General Hospital - Harvard Medical School, 55 Fruit St, Boston, MA 02114, USA.

Background: Local recurrence rates are high in sacral chordoma patients. Adjuvant radiotherapy may play a role in increasing local control. Patients with locally recurrent tumors continue to comprise a significant proportion of the sacral chordoma population and appear to have worse prognosis than those with primary tumors. Read More

View Article
November 2018
5 Reads

A Novel MRI-Based Radiomics Model for Predicting Recurrence in Chordoma.

Conf Proc IEEE Eng Med Biol Soc 2018 Jul;2018:139-142

Chordoma is a rare primary malignant tumor. For evaluating the related factors of postoperative recurrence probability of chordoma before surgery, we retrospective collected 80 patients to analyze by using a novel radiomics method. A total of 620 3D imaging features used for radiomics analysis were extracted, and 5 features were selected from T2-weighted (T2-w) magnetic resonance imaging (MRI) that were most strongly associated with 4-year recurrence probability to build a radiomics signature. Read More

View Article
July 2018
4 Reads

A Triple-Classification Radiomics Model for the Differentiation of Primary Chordoma, Giant Cell Tumor, and Metastatic Tumor of Sacrum Based on T2-Weighted and Contrast-Enhanced T1-Weighted MRI.

J Magn Reson Imaging 2018 Nov 14. Epub 2018 Nov 14.

Department of Radiology, Peking University People's Hospital, Beijing, P. R. China.

Background: Preoperative differentiation between primary sacral chordoma (SC), sacral giant cell tumor (SGCT), and sacral metastatic tumor (SMT) is important for treatment decisions.

Purpose: To develop and validate a triple-classification radiomics model for the preoperative differentiation of SC, SGCT, and SMT based on T2-weighted fat saturation (T2w FS) and contrast-enhanced T1-weighted (CE T1w) MRI.

Study Type: Retrospective. Read More

View Article
November 2018
3 Reads

Rare case of neglected large sacral Chordoma in a young female treated by wide En bloc resection and Sacrectomy.

BMC Cancer 2018 Nov 14;18(1):1112. Epub 2018 Nov 14.

Department of Orthopaedics, Hospital Sultan Ismail, Johor Bahru, Malaysia.

Background: Sacral chordoma is a locally aggressive malignant tumour originating from ectopic notochordal cells. The natural history of sacral chordoma is a slow growing tumour arising at the midline of the lower sacrum that can invade the sacrum and progressively increase in size expanding cranially and anteriorly. Metastasis is very rare even when the tumour is large. Read More

View Article
November 2018
6 Reads

Y-box binding protein-1 promotes tumorigenesis and progression via the EGFR/AKT pathway in spinal chordoma.

Cancer Sci 2018 Nov 13. Epub 2018 Nov 13.

Department of Orthopedics, Peking University Third Hospital, Beijing, China.

Chordomas are rare bone tumors with a poor prognosis and no approved targeted therapy. Y-box binding protein-1 (YBX1) promotes tumor growth, invasion and drug resistance. However, the role of YBX1 in chordoma is unclear. Read More

View Article
November 2018
8 Reads

Differential Diagnosis and Treatment Modality of Parasellar Plasmacytoma: Clinical Series and Literature Review.

World Neurosurg 2018 Nov 7. Epub 2018 Nov 7.

Beijing Neurosurgical Institute, Capital Medical University, Beijing 100050, China.

Background: Parasellar plasmacytomas are rare tumors arising from the sellar region that should be considered in differential diagnosis for lesions involving the sella and clivus. Prior to surgical pathologic examination, parasellar plasmacytomas are often misdiagnosed as invasive pituitary adenomas or chordomas due to the similarity of clinical presentation and imaging findings.

Methods: We retrospectively reviewed 5 patients with parasellar plasmacytoma who underwent endonasal endoscopic tumor resection in Beijing Tiantan Hospital between January 2008 and January 2018. Read More

View Article
November 2018
5 Reads

Giant Recurrent Sacral Chordoma.

World Neurosurg 2018 Nov 1. Epub 2018 Nov 1.

School of Clinical Medicine, Tsinghua University, Beijing, 100084, China; Department of Neurosurgery, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, 102218, China. Electronic address:

View Article
November 2018

Expert's Comment concerning Grand Rounds case entitled "Cryosurgery in the excision of a giant local recurrent sacral chordoma: a case report and literature review" by V. Pipola et al. (Eur Spine J; https://doi.org/10.1007/s00586-017-5438-3).

Eur Spine J 2018 Dec 2;27(12):3064-3065. Epub 2018 Nov 2.

Department of Neurosurgery, Norman Prince Neurosciences Institute, Warren Alpert Medical School of Brown University, Rhode Island Hospital, 593 Eddy Street, Providence, RI, 02903, USA.

View Article
December 2018

Recurrent parachordoma of the lower back: A case report.

Radiol Case Rep 2019 Jan 25;14(1):94-96. Epub 2018 Oct 25.

Moffitt Cancer Center, 12902 Magnolia Dr., Tampa, FL 33612, USA.

Parachordoma is a rare entity with less than 50 cases described in the literature. This soft-tissue tumor resembles chordomas as well as extraskeletal myxoid chondrosarcomas and has only recently been fully characterized. Here we describe the case of a patient with a lower back parachordoma and its subsequent postresection recurrence 9 years after the initial procedure, emphasizing the importance of long-term follow-up in individuals with this diagnosis. Read More

View Article
January 2019

ASO Author Reflections: The Infiltrative Features of Chordoma.

Authors:
Toru Akiyama

Ann Surg Oncol 2018 Oct 29. Epub 2018 Oct 29.

Department of Orthopaedic Surgery, Saitama Medical Center, Jichi Medical University, Saitama, Japan.

View Article
October 2018

The vacuolated morphology of chordoma cells is dependent on cytokeratin intermediate filaments.

J Cell Physiol 2018 Oct 14. Epub 2018 Oct 14.

Fischell Department of Bioengineering, University of Maryland, College Park, MD.

Notochordal cells (NCs), characterized by their vacuolated morphology and coexpression of cytokeratin and vimentin intermediate filaments (IFs), form the immature nucleus pulposus (NP) of the intervertebral disc. As humans age, NCs give way to mature NP cells, which do not possess a vacuolated morphology and typically only express vimentin IFs. In light of their concomitant loss, we investigated the relationship between cytosolic vacuoles and cytokeratin IFs, specifically those containing cytokeratin-8 proteins, using a human chordoma cell line as a model for NCs. Read More

View Article
October 2018
4 Reads

Clinical and Histopathological Findings of Chordomas: a Case Report.

Folia Med (Plovdiv) 2018 Sep;60(3):468-473

Department of Otorhinolaryngology, Faculty of Medicine, Kahramanmaras Sutcu Imam University, Kahramanmaras, Turkey.

Chordomas are rare malignant tumors that develop from the residual of embryonic notochord. These tumors may be seen along the spine and have a local aggressive progression. Skull base chordomas often originate from the clivus as localization. Read More

View Article
September 2018

Benign notochordal cell tumour: clinicopathology and molecular profiling of 13 cases.

J Clin Pathol 2018 Oct 24. Epub 2018 Oct 24.

Department of Neuropathology, Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, China National Clinical Research Center for Neurological Diseases (NCRC-ND), Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing Key Laboratory of Brain Tumor, Beijing, China

Aims: To study the clinicopathological and molecular features of benign notochordal cell tumours (BNCTs) and their differential diagnosis from chordoma.

Methods: 13 cases of BNCT were investigated. The genome-wide copy number imbalances were performed using Oncoscan CNV array in three cases and fluorescence in situ hybridisation (FISH) detection of epidermal growth factor receptor (EGFR)/chromosome 7 enumeration probe (CEP7), LSI1p36/1q21, LSI19p13/19q13, CEP3/CEP12 and Telvysion 6 P was performed in 13 cases. Read More

View Article
October 2018
1 Read

Clinical and radiographic presentation of pelvic sarcoma in children.

SICOT J 2018 19;4:44. Epub 2018 Oct 19.

Department of Orthopaedics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.

Introduction: Pelvic sarcomas may present with vague symptoms. The aim of this study was to examine the characteristics and clinical presentations of different types of pelvic sarcoma in children.

Methods: This is a retrospective cohort study of patients up to 21 years of age with the diagnosis of pelvic sarcoma between January 2000 and June 2013. Read More

View Article
October 2018
2 Reads

Identification of therapeutic targets in chordoma through comprehensive genomic and transcriptomic analyses.

Cold Spring Harb Mol Case Stud 2018 Oct 15. Epub 2018 Oct 15.

St. Joseph's Hospital and Medical Center.

Chordoma is a rare, orphan cancer arising from embryonal precursors of bone. Surgery and radiotherapy (RT) provide excellent local control, often at the price of significant morbidity due to the structures involved and the need for relatively high doses of RTare not typically curative; however, recurrence remains high. Although our understanding of the genetic changes that occur in chordoma is evolving rapidly, this knowledge has yet to translate into treatments. Read More

View Article
October 2018
1 Read

Clinical outcome of proton therapy for patients with chordomas.

Radiat Oncol J 2018 Sep 30;36(3):182-191. Epub 2018 Sep 30.

Department of Neurosurgery, Bundang CHA Medical Center, CHA University College of Medicine, Seongnam, Korea.

Purpose: To investigate the clinical outcome of proton therapy (PT) in patients with chordoma.

Materials And Methods: Fifty-eight patients with chordoma treated with PT between June 2007 and December 2015 at the National Cancer Center, Korea, were retrospectively analyzed. The median total dose was 69. Read More

View Article
September 2018
5 Reads

Commentary: Toward Supratotal Resection of Clival Chordoma: Combined Endoscopic Endonasal and Contralateral Transmaxillary Approaches.

Oper Neurosurg (Hagerstown) 2018 Oct 5. Epub 2018 Oct 5.

Department of Neurosurgery and Skull Base Surgery, Hospital Ernesto Dornelles, Porto Alegre, Brazil.

View Article
October 2018

Far-lateral Transcondylar Approach to Anterior Foramen Magnum Lesions - Our Experience.

Asian J Neurosurg 2018 Jul-Sep;13(3):651-655

Department of Neurosurgery, Bangalore Medical College and Research Institute, Bengaluru, Karnataka, India.

Background: Initial surgical management of the anterior foramen magnum lesions through the posterior approaches was fraught with unacceptable morbidity, mortality, and incomplete removal. The far-lateral approach provides excellent exposure and access to these lesions resulting in complete excision of these lesions with reduced frequency of unwanted complications.

Materials And Methods: Eight patients with lesions anterior to the brainstem and upper cervical cord were surgically treated using the far-lateral transcondylar approach. Read More

View Article
October 2018
8 Reads

Chemoradiotherapy for Unresectable INI1-negative Chordoma in a Child.

J Pediatr Hematol Oncol 2018 Oct 2. Epub 2018 Oct 2.

Department of Pediatrics, Kurashiki Central Hospital.

The characteristics of chordomas in children are distinct from those in adults. In particular, the prognosis of patients with INI1-negative chordoma is dismal. The standard treatment for localized chordoma, complete surgical resection with a wide margin, is seldom feasible for chordomas arising at the clivus in children, mainly due to associated complications. Read More

View Article
October 2018

Comparison of radiomics machine-learning classifiers and feature selection for differentiation of sacral chordoma and sacral giant cell tumour based on 3D computed tomography features.

Eur Radiol 2018 Oct 2. Epub 2018 Oct 2.

Department of Radiology, Peking University People's Hospital, 11 Xizhimen Nandajie, Xicheng District, Beijing, 100044, People's Republic of China.

Objective: We aimed to identify optimal machine-learning methods for preoperative differentiation of sacral chordoma (SC) and sacral giant cell tumour (SGCT) based on 3D non-enhanced computed tomography (CT) and CT-enhanced (CTE) features.

Methods: A total of 95 patients were divided into a training set and a validation set. Three best feature selection methods (Relief, least absolute shrinkage and selection operator (LASSO) and Random Forest (RF)) and three classification methods, including generalised linear models (GLM), support vector machines (SVM) and RF, were compared for their performance in distinguishing SC and SGCT. Read More

View Article
October 2018
1 Read

Three-Dimensional Volume Imaging to Increase the Accuracy of Surgical Management in a Case of Recurrent Chordoma of the Clivus.

Am J Case Rep 2018 Oct 2;19:1168-1174. Epub 2018 Oct 2.

Department of Orthodontics and Radiology, School of Dentistry, University City of São Paulo (UNICID), São Paulo, SP, Brazil.

BACKGROUND The clivus is a depression in the anterior occipital bone of the skull base, posterior to the dorsum sellae, at the junction with the sphenoid bone. Chordoma is a rare tumor arising from embryonic remnants of the notochord and can be locally aggressive with a tendency to recur. The optimal management of this rare tumor remains controversial. Read More

View Article
October 2018
2 Reads

Simultaneous F18-FDG-PET/MR Optimized Treatment Planning in a Young Patient with Sacro-Coccygeal Chordoma.

Klin Padiatr 2018 Oct 1;230(6):326-327. Epub 2018 Oct 1.

Department of Nuclear Medicine, University Hospital of Leipzig, Leipzig.

View Article
October 2018
1 Read

Primary sphenoid lymphoma: Focus on imaging.

Tumori 2018 Oct 1:300891618803501. Epub 2018 Oct 1.

1 Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.

Primary lymphoma of the sphenoid is an extremely rare pathology, therefore it is difficult to hypothesize and the imaging characteristics are not well-known. Here we report the imaging features in computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) scan of a 44-year-old patient who presented with severe headache. CT and MRI showed a sphenoid sinus mass that suggested rhinopharyngeal lesion or a chordoma. Read More

View Article
October 2018
13 Reads

Endoscopic Endonasal Transclival Approach to Tumors of the Clivus and Anterior Region of the Posterior Cranial Fossa (Results of Surgical Treatment of 136 Patients).

World Neurosurg 2018 Sep 24. Epub 2018 Sep 24.

Department of Spine Pathology, N.N. Priorov Central Institute of Traumatology and Orthopedics, Moscow, Russia.

Introduction: With the introduction into the neurosurgical practice of minimally invasive methods using endoscopic techniques, it became possible to effectively remove hard-to-reach tumors, including central tumors of the anterior region of the posterior cranial fossa.

Objective: To analyze the results of surgical treatment of patients with various centrally located tumors of the base of the skull that extend into the anterior region of the posterior cranial fossa using the endoscopic endonasal transclival approach.

Methods: The personal surgical experience of the first author is 136 patients with various tumors (e. Read More

View Article
September 2018
8 Reads

[Application of CyberKnife stereotactic radiosurgery in the treatment of head and neck cancer].

Magy Onkol 2018 Sep 6;62(3):180-185. Epub 2018 Jul 6.

Onkológiai Tanszék, Semmelweis Egyetem, Budapest, Hungary.

The treatment of squamous cell carcinoma of the head and neck is multimodal, including surgery, chemotherapy, and radiotherapy, or the combination of those. Though aggressive treatment results in complete tumor remission in many patients even in locally advanced stages, unfortunately local relapse is not uncommon. For patients not candidate for salvage surgery, chemotherapy and conventional fractionated external beam irradiation can be applied. Read More

View Article
September 2018
10 Reads

Characterization of a Clival Chordoma Xenograft Model Reveals Tumor Genomic Instability.

Am J Pathol 2018 Dec 22;188(12):2902-2911. Epub 2018 Sep 22.

Division of Neurosurgery, The Hospital for Sick Children, Toronto, Ontario, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada; Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.

Patient-derived xenografts retain the genotype of the parent tumors more readily than tumor cells maintained in culture. The two previously reported clival chordoma xenografts were derived from recurrent tumors after radiation. To study the genetics of clival chordoma in the absence of prior radiation exposure we established a patient-derived xenograft at primary resection of a clival chordoma. Read More

View Article
December 2018
3 Reads

Partially ablative radiotherapy (PAR) for large mass tumors using simultaneous integrated boost: A dose-escalation feasibility study.

J Appl Clin Med Phys 2018 Nov 15;19(6):35-43. Epub 2018 Sep 15.

Radiation Oncology Department, DIMES Università di Bologna - Ospedale S.Orsola Malpighi, Bologna, Italy.

Purpose: This study aimed to assess the feasibility to plan and deliver highly heterogeneous doses to symptomatic large tumors using volumetric modulated arc therapy (VMAT) and simultaneous integrated boost (SIB) during a short course palliative accelerated radiotherapy.

Methods: A patient with a large symptomatic chordoma infiltrating the right gluteal region was selected. A modified SIB treatment was implemented to irradiate the central volume of the tumor (boost target volume, BTV) up to 10 Gy/fraction in a dose escalation trial while maintaining the remaining tumor volume (planning target volume, PTV) and the surrounding healthy tissues within 5 Gy/fraction in twice daily fractions for two consecutive days. Read More

View Article
November 2018

Chordoma: a systematic review of the epidemiology and clinical prognostic factors predicting progression-free and overall survival.

Eur Spine J 2018 Dec 15;27(12):3043-3058. Epub 2018 Sep 15.

Department of Neurosurgery, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.

Background And Aims: The aim of this systematic review is to describe the epidemiology of chordoma and to provide a clear overview of clinical prognostic factors predicting progression-free and overall survival.

Methods: Four databases of medical literature were searched. Separate searches were performed for each of the two objectives. Read More

View Article
December 2018

Clinicocytopathological spectrum, including uncommon forms, of nine cases of chordomas with immunohistochemical results, including brachyury immunostaining: A single institutional experience.

Cytopathology 2018 Sep 15. Epub 2018 Sep 15.

Department of Surgical Pathology, Tata Memorial Hospital, Mumbai, India.

Objectives: To present clinical and cytopathological features of nine cases of chordomas, diagnosed over 9 years and confirmed by brachyury (T) immunostaining.

Methods: Conventional cytological smears, stained with Papanicolaou and May-Grünwald Giemsa, along with corresponding histopathological (n = 8) and immunostained sections (n = 8) were reviewed. Immunohistochemical staining was performed on tissue sections by polymer detection technique. Read More

View Article
September 2018

Influence of silibinin and β-β-dimethylacrylshikonin on chordoma cells.

Phytomedicine 2018 Oct 12;49:32-40. Epub 2018 Jun 12.

Department of Pharmacognosy, Institute of Pharmaceutical Sciences, University of Graz, Graz, Austria.

Background: Chordoma, slow growing bone tumours originating from remnants of the notochord, leave affected patients with a median survival of six years. The high recurrence rate of chordoma, together with limited treatment options and bad overall prognosis, make the development of new treatment options urgently necessary.

Purpose: In this study, the potential of two natural products, silibinin and β-β-dimethylacrylshikonin (DMAS), was tested on clival (MUG-CC1 and UM-Chor1) as well as sacral (MUG-Chor1 and U-CH2) chordoma cell lines. Read More

View Article
October 2018
1 Read
3.130 Impact Factor

Imatinib and everolimus in patients with progressing advanced chordoma: A phase 2 clinical study.

Cancer 2018 Oct 14;124(20):4056-4063. Epub 2018 Sep 14.

Medical Oncology Unit 2, Medical Oncology Department, Fondazione IRCCS Istituto Nazione dei Tumori, Milan, Italy.

Background: We present the results of an academic phase 2 study on imatinib plus everolimus in patients who have progressive advanced chordoma.

Methods: In January 2011, 43 adult chordoma patients were enrolled in the study and received imatinib 400 mg/day and everolimus 2.5 mg/day until progression or limiting toxicity. Read More

View Article
October 2018

Extreme lateral transodontoid approach to the ventral craniocervical junction: cadaveric dissection and case illustrations.

J Neurosurg 2018 Sep 14:1-11. Epub 2018 Sep 14.

Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, Salt Lake City, Utah.

OBJECTIVE Surgical treatment of pathological processes involving the ventral craniocervical junction (CCJ) traditionally involves anterior and posterolateral skull base approaches. In cases of bilateral extension, when lesions extend beyond the midline to the contralateral side, a unilateral corridor may result in suboptimal resection. In these cases, the lateral extent of the tumor will prevent extirpation of the lesion via anterior surgical approaches. Read More

View Article
September 2018
1 Read

A Staged Strategy for Craniocervical Junction Chordoma with Combination of Endoscopic Endonasal Approach and Far Lateral Approach with Endoscopic Assistance: Case Report.

J Neurol Surg B Skull Base 2018 Oct 16;79(Suppl 4):S371-S377. Epub 2018 Jul 16.

Department of Neurosurgery, Lariboisière Hospital, University of Paris Diderot, Paris, France.

 While the endoscopic endonasal approach (EEA) has gained widespread acceptance for the resection of clivus chordomas, conventional transcranial approaches still have a crucial role in craniocervical junction (CCJ) chordoma surgery. In repeat surgery, a carefully planned treatment strategy is needed. We present a surgical treatment plan combining an EEA and a far-lateral craniotomy with endoscopic assistance (EA) in the salvage surgery of a recurrent CCJ chordoma. Read More

View Article
October 2018
1 Read

Surgical Treatment of Sacral Chordoma: En Bloc Resection with Negative Margins is a Determinant of the Long-Term Outcome.

Surg Technol Int 2018 Nov;33:343-348

Department of Orthopedic Surgery, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.

Study Design: Retrospective case series.

Objective: To report the outcome of a series of patients with sacral chordoma who were surgically treated at a single center.

Summary: Chordomas are low-grade malignant tumors that arise from remnants of the notochord. Read More

View Article
November 2018
1 Read

Clival chordoma: long-term clinical outcome in a single center.

Medicine (Baltimore) 2018 Sep;97(36):e12207

Department of Orthopedics, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.

The treatment of clival chordoma remains highly challenging. This difficulty is enhanced by the very small likelihood of a successful complete surgical resection or nonsurgical treatment of chordoma. Additionally, no effective means of interdisciplinary treatment for chordoma have been identified. Read More

View Article
September 2018
13 Reads

Updates in Primary Bone Tumors: Current Challenges and New Opportunities in Cytopathology.

Authors:
Xiaohua Qian

Surg Pathol Clin 2018 Sep;11(3):657-668

Department of Pathology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA. Electronic address:

The review summarizes the current diagnostic challenges in fine-needle aspiration of primary bone tumors, with focus on the application of new molecular and immunohistochemical techniques in the diagnosis of giant cell-rich neoplasms, chondrosarcomas, and notochordal tumors. Read More

View Article
September 2018
8 Reads

Supratotal Resection of Residual Clival Chordoma With Combined Endoscopic Endonasal and Contralateral Transmaxillary Approaches: 2-Dimensional Operative Video.

Oper Neurosurg (Hagerstown) 2018 Sep 4. Epub 2018 Sep 4.

Department of Otolaryngology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

The optimal treatment for skull base chordomas is gross total resection followed by radiotherapy and not radiation of partially resected tumors. Supratotal resection, defined as removal beyond all involved bone and dura, is ideal but difficult to achieve. In this video, we present the case of a 37-yr-old man with new onset of progressive cranial nerve sixth palsy and a skull base lesion compatible with clival chordoma. Read More

View Article
September 2018
1 Read